PDCD1 and neoplasm: It would therefore stand to reason that anti-PD1 based immunotherapy should be evaluated as first line therapy for unresectable or metastatic cutaneous sarcomas, even when alternative options with anti-tumor efficacy exist, e.g. taxane-based cytotoxic chemotherapy for cutaneous angiosarcoma.